What is Lamivir-S 30
Lamivir-S 30 is comprised of 30mg of stavudine and 150mg of lamivudine and is used to prevent the multiplication of human immunodeficiency virus (HIV). If you have an HIV infection, this form of treatment may be right for you. This combination drug allows for an easier therapy regime.
If your body weight is less than 60kg and you don’t have low creatinine clearance, you may take Lamivir-S 30. Take 1 tablet every 12 hours, with or without food. Taking this medication improperly may result in reduced efficacy. If you accidentally miss a dose, take your next scheduled dose. Do not take a double dose to compensate for any forgotten tablet. This medication is not suitable for those who require an adjustment dose of stavudine or lamivudine. Take the medication exactly as directed by your doctor.
Do not use Lamivir-S 30 if you are allergic to lamivudine, stavudine, or any of this medication’s other ingredients.
You may experience side effects when taking Lamivir-S 30 therapy, including:
- Upper respiratory tract infections (i.e. sore throat, nasal infection, throat infection);
- Body chills;
- Muscle aches.
Rarer side effects documented in association with Lamivir-S 30 therapy include:
- Motor weakness;
- Hepatic toxicity;
- Hepatic decompensation in patients with both hepatitis C and HIV-1 infections;
- Lactic acidosis and severe hepatomegaly with steatosis.
Severe cases of lactic acidosis (including fatalities) have been reported in patients taking nucleoside analogues like Lamivir-S 30. This condition is characterized by the abnormal accumulation of lactic acid in the bloodstream, which lowers the overall pH of the blood. Particular risk factors for this condition include being female or obese. Consult with your doctor prior to starting therapy with this medication.
Since there are 2 active ingredients in this drug, the possibility of drug interaction is high. If you are on any medications, please contact a doctor to ensure that they will not cause harm.
- Drugs that can interact with lamivudine:
- Interferon- and ribavirin- based medications;
- Drugs that can interact with stavudine:
Pregnancy & Lactation
After intensive animal-based studies, Lamivir-S 30 has been logged under category C in the FDA’s Pregnancy Categories. As such, pregnant women should be cautious when using this medication: it should only be taken if its potential benefits justify any potential risks to an unborn child. Moreover, it is not yet known if this drug is excreted in breast milk. Because of this, breastfeeding patients should consult a doctor about safe breastfeeding practices if they are prescribed with Lamivir-S 30.
There is no known antidote for overdose with this medication. As such, please take precautions when using Lamivir-S 30 to ensure that no more than the recommended amount is taken. If overdose occurs, seek immediate medical attention. You must be monitored continuously using suitable supportive treatment methods.
Alternative Brand Names
Lamivir-S 30 is also marketed internationally, including the US and Canada, under the brand names Emduo 30 and Lamistar.
Reviews are only written by verified customers who have purchased this product.